Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCardiol Therapeutics Inc Class A

Cardiol Therapeutics Inc Class A

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
1.42 CAD -0.08 ( 5.33%)
Last update at 2026-11-04T20:50:00Z
VOLUME
70823
Market Cap
249.05M

Momentum Score

…

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.41
Low
1.51
High
52 Week Price Range
1.23
Low
2.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cardiol Therapeutics is a clinical-stage Canadian biotechnology company developing proprietary cannabidiol-based intravenous and oral therapies for inflammatory-mediated heart disease and heart failure. Long-term growth may be supported by positive clinical data, regulatory approvals, licensing or partnership arrangements, and successful commercialization in unmet cardiac markets, which could make the company attractive to investors seeking exposure to novel cardiology treatments.
Principal risks include clinical trial and safety outcome uncertainty, the likely need for additional financing that could dilute shareholders, and competitive and commercial execution challenges that may impede value creation.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.50
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.08M
Debt / Equity
0.01
ROE
-158.75%
Net Debt
-21.29M
ROCE
-191.02%
Diluted EPS TTM
-0.42

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -33.82M -36.68M -28.13M -30.93M -31.64M
Net income -33.82M -36.68M -28.13M -11.52M -31.74M
Selling general administrative 20.20M 26.26M 15.56M 22.37M 27.87M
Selling and marketing expenses - - 15.30M - -
Gross profit - -0.37M -0.25M - 0.08M
Reconciled depreciation 0.10M 0.37M 0.24M 0.22M 0.22M
Ebit -34.32M -36.68M -28.13M -50.34M -45.47M
Ebitda -34.21M -36.30M -27.88M -50.12M -45.25M
Depreciation and amortization 0.10M 0.37M 0.25M 0.22M 0.22M
Operating income -34.32M -40.28M -29.79M -50.34M -45.47M
Other operating expenses 34.32M -40.28M 30.17M 41.34M 38.74M
Interest expense - - - 19.41M 0.11M
Interest income 0.73M 3.57M 2.17M 1.24M 6.91M
Net interest income 0.73M 1.19M 2.17M 1.24M 0.11M
Income tax expense - - 0.00M -19.41M 0.11M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.08M
Total operating expenses 34.32M 39.90M 29.54M 41.34M 38.74M
Cost of revenue - 0.37M 0.25M - -
Total other income expense net 0.50M 3.60M 1.66M 19.41M 13.83M
Net income from continuing ops -33.82M -36.68M -28.01M -30.93M -31.64M
Net income applicable to common shares - -36.68M -28.13M -30.93M -31.64M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 23.62M 31.86M 36.70M 62.03M 87.88M
Intangible assets - - 0.21M 0.29M 0.38M
Other current assets 1.86M - 0.94M - 2.83M
Total liab 5.74M 7.14M 8.45M 9.83M 11.64M
Total stockholder equity 17.88M 24.73M 28.25M 52.20M 76.24M
Other current liab 5.62M - 8.28M 9.75M 11.52M
Common stock 201.87M - 148.52M 147.55M 142.92M
Capital stock 201.87M 179.34M - 147.55M 142.92M
Retained earnings -213.07M -179.25M -142.58M -114.45M -83.52M
Other assets - - 0.00M - -
Cash 21.42M 30.58M 34.87M 59.47M 83.90M
Cash and equivalents - - - 59.47M 83.90M
Total current liabilities 5.66M 7.01M 8.30M 9.80M 11.57M
Current deferred revenue - - -7.62M - -
Net debt -21.29M - -34.70M -59.40M -83.78M
Short term debt 0.04M - 0.02M 0.05M 0.04M
Short long term debt total 0.13M - 0.17M 0.07M 0.12M
Other stockholder equity 29.08M - 18.79M 19.10M 16.84M
Property plant equipment - - - 0.30M 0.36M
Total current assets 23.50M 31.67M 36.15M 61.44M 87.14M
Net tangible assets - - - 51.91M 75.86M
Short term investments - - 0.06M - -
Net receivables 0.23M 0.10M 0.28M 0.48M 0.41M
Inventory - - - - 0.34M
Accounts payable - - 7.62M 9.33M 4.14M
Accumulated other comprehensive income - - 3.52M - -
Non currrent assets other - - -0.00M - -
Non current assets total 0.12M 0.20M 0.55M 0.59M 0.74M
Capital lease obligations 0.13M 0.16M - 0.07M 0.12M
Long term debt total - - - 0.02M 0.07M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.02M -0.10M -0.07M -0.01M
Change to liabilities - - - 4.47M 2.39M
Total cashflows from investing activities -0.02M -0.02M -0.06M -0.07M -0.01M
Net borrowings -0.06M -0.04M -0.06M -0.05M -0.05M
Total cash from financing activities 15.54M 18.84M -0.06M -0.05M 93.44M
Change to operating activities - - - 1.42M -2.27M
Net income -33.82M -36.68M -28.13M -30.93M -31.64M
Change in cash -9.16M -4.35M -24.54M -24.43M 69.87M
Begin period cash flow 30.58M 34.93M 0.06M 83.90M 14.03M
End period cash flow 21.42M 30.58M 0.03M 59.47M 83.90M
Total cash from operating activities -23.85M -25.06M -25.18M -27.22M -23.55M
Issuance of capital stock 16.04M 21.36M 0.00M 0.00M 84.08M
Depreciation 0.10M 0.37M 0.25M 0.22M 0.22M
Other cashflows from investing activities - - -0.06M - -
Change to inventory - - 0.00M 0.00M 0.02M
Change to account receivables 0.14M -0.08M 0.07M -0.14M -0.06M
Sale purchase of stock - 21.53M - 0.00M 98.73M
Other cashflows from financing activities -0.48M -2.47M -0.06M -0.07M 9.41M
Change to netincome - - - -2.26M 7.79M
Capital expenditures 0.02M 0.02M 0.00M 0.07M 0.01M
Change in working capital -0.73M -0.93M 0.75M 5.75M 0.08M
Stock based compensation 10.70M 14.28M 4.17M 5.01M 8.50M
Other non cash items -0.11M -2.10M -0.63M -7.27M -0.71M
Free cash flow -23.88M -25.08M -0.03M -27.30M -23.56M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CRDL
Cardiol Therapeutics Inc Class A		 -0.08
5.33%		 1.42 - - 1004.11 12.81 293.71 0.41
CURA
Curaleaf Holdings Inc.		 -0.74
5.20%		 13.49 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.31
2.72%		 11.72 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.16
3.36%		 4.92 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 0.41
11.02%		 4.13 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Cardiol Therapeutics Inc Class A

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5

289 910 0850

https://www.cardiolrx.com

18

Name Title Year Born
Mr. David G. Elsley M.B.A., MBA Pres, CEO & Director NA
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, M.B.A., MBA CFO, Corp. Sec. & Director NA
Mr. Bernard Lim B.Sc. Chief Operating Officer NA
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer & Head of R&D 1962
Trevor Burns Investor Relations NA
Mr. David G. Elsley MBA President, CEO & Director NA
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA CFO, Corporate Secretary & Director NA
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer & Head of Research & Development 1962
Mr. John A. Geddes BSCPT, MBA Vice President of Corporate Development NA
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer and Head of Research & Development 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…